HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplementary data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by von Lilienfeld-Toal, M. Articles by Glasmacher, A. Search for Related Content PubMed PubMed Citation Articles by von Lilienfeld-Toal, M. Articles by Glasmacher, A.

A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy

^* Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Bonn;
^° Klinikum Region Hannover, Siloah, Medizinische Klinik III, Hannover;
^# GPR Klinikum, I. Medizinische Klinik, Rüsselsheim;
^@ Ernst-Moritz-Arndt-Universität Greifswald, Klinik und Poliklinik für Innere Medizin C, Diagnostikzentrum, Greifswald, Germany

Correspondence: Marie von Lilienfeld-Toal, Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud Str. 25, 53105 Bonn. Phone: international +49.22828714003. E-mail: m.lilienfeld.toal{at}uni-bonn.de

We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive GCSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.